Updates are available Correction dated 2022-09-13
Click to view Correction: https://doi.org/10.1038/s41591-022-02037-1
-
Authors
Milà-Alomà, Marta
Ashton, Nicholas J.
Shekari, Mahnaz
Salvadó, Gemma
Ortiz-Romero, Paula http://orcid.org/0000-0002-6378-6763
Montoliu-Gaya, Laia http://orcid.org/0000-0001-7684-6318
Benedet, Andrea L.
Karikari, Thomas K. http://orcid.org/0000-0003-1422-4358
Lantero-Rodriguez, Juan http://orcid.org/0000-0002-7426-678X
Vanmechelen, Eugeen http://orcid.org/0000-0002-9466-5366
Day, Theresa A.
González-Escalante, Armand
Sánchez-Benavides, Gonzalo
Minguillon, Carolina
Fauria, Karine
Molinuevo, José Luis
Dage, Jeffrey L. http://orcid.org/0000-0002-2192-1699
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Gispert, Juan Domingo
Suárez-Calvet, Marc http://orcid.org/0000-0002-2993-569X
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
- License Information
-
More Information
Article History
Received: 27 July 2021
Accepted: 29 June 2022
First Online: 11 August 2022
Competing interests
: E.V. is a co-founder of ADx NeuroSciences. T.A.D. is an employee and shareholder of Eli Lilly and Company. J.L.M. is currently a full-time employee of Lundbeck and has previously served as a consultant or on advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare and ProMIS Neurosciences. J.L.D. has served as a consultant for Genotix Biotechnologies Inc., Gates Ventures, Karuna Therapeutics, AlzPath Inc. and Cognito Therapeutics, Inc. J.L.D. received research support from ADx Neurosciences, Roche Diagnostics and Eli Lilly and Company in the past 2 years. H.Z. has served on scientific advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS). J.D.G. has received speaker’s fees from Philips and Biogen and research support from GE Healthcare, Roche and Roche Diagnostics. M.S.C. has served as a consultant and on advisory boards for Roche Diagnostics International Ltd, and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U. and Roche Farma, S.A. K.B. has served as a consultant, on advisory boards or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Roche Diagnostics and Siemens Healthineers, and is a co-founder of BBS in Gothenburg. The remaining authors declare no competing interests.
